Protet-IG IM Injection

Introduction

Protet-IG IM Injection 250 IU/ml (HTIG) is a preparation of pooled human immunoglobulins that contains antibodies against tetanus toxin. It is used as a passive immunization to prevent or treat tetanus infections in individuals who have been exposed to the tetanus bacterium or who are at high risk of tetanus.

Uses

Protet-IG IM Injection 250 IU/ml is used for:

Post-exposure prophylaxis in individuals who have not been adequately vaccinated against tetanus or whose vaccination status is unknown, especially after a tetanus-prone wound.
Treatment of tetanus infection, in conjunction with tetanus toxoid vaccination and appropriate wound management.
Providing immediate but temporary immunity in cases where active immunization with tetanus toxoid is not possible.

Brand Name	Protet-IG
Type	IM Injection
Weight	250 IU/ml
Generic	Human Tetanus Immunoglobulin
Manufacturer	Incepta Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Protet-IG IM Injection 250 IU/ml provides passive immunity by supplying antibodies against the tetanus toxin. These antibodies neutralize the toxin and prevent its binding to nerve endings, thus preventing the progression of tetanus and aiding in the resolution of the infection.

How Long Does It Take to Work?

The effects of Protet-IG IM Injection 250 IU/ml are typically immediate, providing prompt protection against the tetanus toxin. However, it is used in conjunction with tetanus toxoid to provide long-term immunity.

Absorption

Protet-IG IM Injection 250 IU/ml is administered intramuscularly, and its components are rapidly absorbed into the bloodstream.

Route of Elimination

The antibodies in Protet-IG IM Injection 250 IU/ml are gradually broken down by the body, with their elimination primarily occurring through the reticuloendothelial system. The half-life of these immunoglobulins varies but is generally around 2-3 weeks.

Dosage

Post-exposure prophylaxis of tetanus:

For adults and children single dose of 250 IU should be given. The dose may be increased to 500 IU in case of:
Infected wounds where surgically appropriate treatment cannot be achieved within 24 hours
Deep or contaminated wounds with tissue damage and reduced oxygen supply, as well as foreign body injury (e.g., bites, stings or shots)
Burns, congelations
Tissue necrosis
Septicaemic abortion
Adults weighing more than the average

In case of extensive bums, it is advisable to administer a second injection of 250 IU human tetanus immunoglobulin after the exsudative phase of the burn has subsided (about 36 hours after onset of the bum).

At the same time, 0.5 ml of tetanus vaccine in a different extremity with a separate syringe and complete immunization schedule is required to be administered.

Therapy of clinically manifest tetanus: For adults and children single doses of 3,000 to 6,000 IU (in combination with other appropriate clinical procedures).

The dosage of Protet-IG IM Injection 250 IU/ml depends on the clinical situation and the patient's exposure history:

For post-exposure prophylaxis: Typically, 250 units administered intramuscularly as a single dose.
For treatment of tetanus: Dosage may be higher and is tailored to the severity of the infection and patient needs.

Administration

Protet-IG IM Injection 250 IU/ml is administered intramuscularly, usually in the deltoid muscle. It should be given as soon as possible after exposure to tetanus or in the presence of a tetanus-prone wound.

Side Effects

Common side effects may include:

Local reactions at the injection site, such as pain, swelling, or redness.
Mild fever.
Allergic reactions, though rare.

Toxicity

Protet-IG IM Injection 250 IU/ml is generally well-tolerated. Toxicity is rare but may include severe allergic reactions or anaphylaxis. In such cases, immediate medical attention is required.

Precautions

Precautions include:

Monitor for allergic reactions, especially in patients with a history of hypersensitivity to immunoglobulins.
Use with caution in patients with a history of severe adverse reactions to previous doses of immunoglobulins.

Interaction

Protet-IG IM Injection 250 IU/ml should be used in conjunction with tetanus toxoid to ensure effective immunization. It may interfere with the immune response to live vaccines if given simultaneously or within a short time frame.

Disease Interaction

Use with caution in patients with autoimmune disorders or immunodeficiencies, as their immune response may be compromised.

Drug Interaction

Protet-IG IM Injection 250 IU/ml may interact with live vaccines. It is advisable to separate the administration of immunoglobulins and live vaccines by several weeks.

Food Interactions

There are no known food interactions with Protet-IG IM Injection 250 IU/ml. Patients can maintain a normal diet.

Pregnancy Use

Protet-IG IM Injection 250 IU/ml is generally considered safe during pregnancy. It is used when indicated to protect both the mother and fetus from tetanus exposure.

Lactation Use

Protet-IG IM Injection 250 IU/ml is also considered safe for use during lactation. It does not affect breastfeeding or the infant adversely.

Acute Overdose

Acute overdose is unlikely due to the controlled dosing of Protet-IG IM Injection 250 IU/ml. If an excessive amount is administered, it may lead to increased risk of side effects, such as severe allergic reactions.

Contraindication

Contraindications include:

Known hypersensitivity to immunoglobulins or any component of the preparation.
History of severe allergic reactions to previous doses.

Use Direction

Administer Protet-IG IM Injection 250 IU/ml intramuscularly as directed by a healthcare provider. Follow the recommended dosage and administration schedule, and ensure it is given promptly after exposure to tetanus or in a tetanus-prone situation.

Storage Conditions

Store Protet-IG IM Injection 250 IU/ml in a refrigerator at 2-8°C (36-46°F). Do not freeze. Keep it out of reach of children and protect it from light.

Volume of Distribution

The volume of distribution for immunoglobulins is generally around 5-7 liters in the human body. Specific values for Protet-IG IM Injection 250 IU/ml are not typically detailed.

Half Life

The half-life of Protet-IG IM Injection 250 IU/ml is approximately 2-3 weeks. This duration may vary based on individual patient factors and response to treatment.

Clearance

Protet-IG IM Injection 250 IU/ml is cleared from the bloodstream gradually through the reticuloendothelial system, with the rate of clearance depending on the individual’s metabolism and immune response.

See in details version Protet-IG IM Injection 250 IU/ml also Protet-IG IM Injection 250 IU/ml in bangla